Physician profile
James Jackson
NPI 1730115528
$3,349.78
in general payments reported to CMS, 2019-2025
24 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $100 · 2021: $326 · 2022: $559 · 2023: $463 · 2024: $766 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,122.90 | 2019-2025 | |
| Janssen Biotech, INC. | $716.40 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $426.90 | 2019-2025 | |
| Celgene Corporation | $281.18 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $124.30 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $114.49 | 2024-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $103.22 | 2021-2024 | |
| Lilly USA, LLC | $81.98 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $76.07 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.01 | 2022-2023 | Xifaxan |
| Horizon Therapeutics Plc | $40.16 | 2019-2020 | |
| Qol Medical, LLC | $26.26 | 2019-2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $22.92 | 2025 | Eohilia |
| Madrigal Pharmaceuticals | $20.88 | 2024 | Resmetirom |
| Daiichi Sankyo INC. | $18.68 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17.94 | 2025 | Voquezna |
| Amag Pharmaceuticals, INC. | $16.19 | 2021 | |
| Evoke Pharma, INC. | $16.07 | 2024 | |
| Aimmune Therapeutics, INC. | $15.66 | 2024 | |
| Novo Nordisk INC | $14.32 | 2025 | Ozempic, Rybelsus |
| Genzyme Corporation | $14.25 | 2025 | |
| Boston Scientific Corporation | $12.83 | 2021 | |
| Endogastric Solutions, INC | $8.17 | 2023 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$99,979.45 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.